Liangzhong Sun

Liangzhong Sun

paediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
DLDantong Li
Dantong Li
MHMiaoyue Hu
Miaoyue Hu
HCHuamu Chen
Huamu Chen
XWXiaohong Wu
Xiaohong Wu
XWXiaoya Wei
Xiaoya Wei
LSLiangzhong Sun
Liangzhong Sun
Nephronophthisis (NPH) is the most prevalent monogenetic disorder leading to end-stage renal failure (ESRD) in childhood. Mutations in Nphp1, encoding a cilia-localized protein, account for the majority of NPH cases. Despite its identification many years ago, Nphp1 deletions targeting exon 4 or exon 20 have not reproduced the histological features of human NPH in murine models. In this study, we deleted exon 2–20 of Nphp1 by CRISPR/Cas9 gene editing to create a near-total knockout (KO) mouse model (Nphp1del2–20/del2–20). Nphp1del2–20/del2–20 mice faithfully reproduced the renal and extrarenal phenotypes associated with human NPH, including renal cyst development, tubular basement membrane thickening, retinal degeneration and abnormal spermatogenesis. Importantly, Nphp1 re-expression using an adenoviral-associated-virus-9 vector could partially rescue both renal and retinal phenotypes in Nphp1del2–20/del2–20 mice. Our results reported the first relevant Nphp1 mouse model with renal phenotypes for human disease. It will be a valuable model for future studies of Nphp1 function and to develop novel treatments for this common childhood disease.

1 July 2014 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
LSLiangzhong Sun
Liangzhong Sun
HWHaiyan Wang
Haiyan Wang
XJXiaoyun Jiang
Xiaoyun Jiang
YMYing Mo
Ying Mo
ZYZhihui Yue
Zhihui Yue
TLTing Liu
Ting Liu
Objective.: To explore the clinical and pathological features of microscopic polyangiitis (MPA) in children.Methods.: A retrospective analysis was performed of patients with pediatric MPA in our hospital over 10 years.Results.: Data for 20 patients were collected; 16 patients had primary MPA (4 boys, 12 girls), with a median age of 8.9 years at the time of disease onset; 4 patients, all female, had antithyroid drug (ATD)-associated MPA, with an age range of 12.5 to 16.2 years at the time of disease onset. All patients exhibited renal involvement. Renal biopsies were performed in 14 patients. Fibrinoid exudation and necrosis of the glomerular capillaries were observed in all biopsy specimens. Crescents and scleroses were noted in 92.9% and 85.7% of these cases, respectively. The most frequent extrarenal organs involved were lungs, followed by the central nervous system (CNS), skin, and digestive system. Ninety percent of patients were positive for perinuclear antineutrophil cytoplasmic antibody, 94.1% were positive for myeloperoxidase, and 88.2% were positive for both. Forty-five percent of the patients had received steroid plus cyclophosphamide (CTX) pulse therapy for more than 3 months, and varying degrees of remission had been achieved in 88.9% of the patients.Conclusion.: Both primary and ATD-associated MPA showed a female predisposition. Renal involvement was the most frequently observed condition, followed by involvement of lungs. CNS involvement was not rare in these pediatric patients. The efficacy of steroid plus CTX as induction therapy was evident in these patients.

28 January 2016 in Nephrology
Verified
Journal Article
Closed access
PDF file
LSLiangzhong Sun
Liangzhong Sun
HTHuajuan Tong
Huajuan Tong
HWHaiyan Wang
Haiyan Wang
ZYZhihui Yue
Zhihui Yue
TLTing Liu
Ting Liu
CWChangxi Wang
Changxi Wang

14 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HWHaiyan Wang
Haiyan Wang
ZYZhihui Yue
Zhihui Yue
JWJinlang Wu
Jinlang Wu
TLTing Liu
Ting Liu
YMYing Mo
Ying Mo
LSLiangzhong Sun
Liangzhong Sun
The pathogenesis of proteinuria in Alport syndrome (AS) remains unclear. Vascular endothelial growth factor A (VEGFA) is a key regulator of the glomerular filtration barrier (GFB). This study explored the expression of VEGFA in the glomeruli and its accumulation in the glomerular basement membrane (GBM) and their relationship with podocyte injury and proteinuria in Alport syndrome (AS). Clinical data and renal tissues of control patients (11 cases) and AS patients (25 cases) were included. AS patients were further divided into 2 groups according to the quantities of their urinary protein: mild to moderate proteinuria group (proteinuria <50 mg/kg/d, 15 cases) and heavy proteinuria group (proteinuria ≥50 mg/kg/d, 10 cases). The expression and distribution of VEGFA and VEGF receptor 2 (VEGFR2) in the GFB, the phosphorylation of VEGFR2 (p-VEGFR2) and nephrin (p-nephrin), and the expression of synaptopodin and nephrin in the glomeruli were detected by immune electron microscopy and/or immunofluorescence, and their relationships to proteinuria in AS patients were analyzed. The accumulation of VEGFA in the GBM was increased in AS patients. The expression of VEGFA and the levels of p-VEGFR2 and p-nephrin in glomeruli were increased and were positively correlated with the degree of proteinuria in AS patients. The expression of synaptopodin and nephrin were decreased and were negatively correlated with the degree of proteinuria in AS patients. The over expressed VEGFA in the glomeruli and its accumulation in the GBM may activate the VEGFA-VEGFR2 and nephrin signaling pathways and lead to podocyte injury and occurrence of proteinuria in AS.

1 November 2020 in Kidney Medicine
Verified
Journal Article
Open access
DLDantong Li
Dantong Li
LSLiangzhong Sun
Liangzhong Sun
Important advances have been made regarding the diagnosis and management of polycystic kidney diseases. Care of patients with polycystic kidney diseases has moved beyond supportive care for complications and chronic kidney disease to new potentially disease-modifying therapies. Recently, the role of noncoding RNAs, in particular microRNAs, has been described in polycystic kidney diseases. microRNAs are involved in the regulation of gene expression, in which PKD1, PKD2, and other genes that contribute to the pathogenesis of polycystic kidney diseases are considerable participants. Seminal studies have highlighted the potential importance of microRNAs as new therapeutic targets and innovative diagnostic and/or prognostic biomarkers. Furthermore, an anti–miR-17 drug has advanced through preclinical autosomal dominant polycystic disease studies, and an anti–miR-21 drug has already cleared a phase 1 clinical trial. Most probably, new drugs in the microRNA research field will be yielded as a result of ongoing and planned therapeutic trials. To provide a foundation for understanding microRNA functions as a disease-modifying therapeutic drug in novel targeted therapies, in this narrative review we present an overview of the current knowledge of microRNAs in the pathogenesis of polycystic kidney diseases.

1 January 2021 in Renal Failure
Verified
Journal Article
Open access
MLMin Li
Min Li
ZYZhihui Yue
Zhihui Yue
HLHongrong Lin
Hongrong Lin
HWHaiyan Wang
Haiyan Wang
HCHuamu Chen
Huamu Chen
LSLiangzhong Sun
Liangzhong Sun
Coenzyme Q10 (CoQ10) is involved in the biosynthesis of adenosine triphosphate (ATP), and is most abundant in the mitochondrial membrane. The primary CoQ10 deficiency caused by COQ2 defect is mostl...